Retrospective Study of Outcome in Patients Treated for Staphylococcus

Total Page:16

File Type:pdf, Size:1020Kb

Retrospective Study of Outcome in Patients Treated for Staphylococcus ORIGINAL ARTICLE Retrospective study of outcome in patients treated for Staphy 1ococcus aureus b ac teremia Pauline E. Gosdenl, Barnaby C. Reeves2,]ames R. S. Osborne3, Andrew Turner' and Michael R. Millarl 'Department of mcrobiology, 2Research and Development Support Unit, and 3Department of Pathology, University of Bristol, Bristol Royal Infirmary, United Bristol Healthcare Trust, Bristol, UK Objective: To investigate whether a change in current treatment practice for Staphylococcus aureus bacteremia from flucloxacillin and aminoglycoside to flucloxacillin and fusidic acid was associated with any changes in outcome. Methods: A retrospective analysis was carried out of 316 episodes of S. aureus bacteremia diagnosed and treated in a tertiary hospital complex between 1983 and 1993. Outcomes considered were (1) death related to the infection and (2) relapse following cessation of antibiotic therapy. Results: Mortality related to infection, which occurred in 24% of patients, was unrelated to treatment with the combination of flucloxacillin and fusidic acid; however, increasing age was a significant risk factor (OR per decade = 1.35, 95% CI = 1.1&1.55), and increasing duration of treatment (OR per week of treatment = 0.63,95% CI = 0.52-0.77), use of flucloxacillin (OR= 0.30,95% CI = 0.14-0.64). presence of an intravascular device (OR= 0.39,95% CI = 0.20-0.78) and presence of a skin lesion (OR = 0.51, 95% CI = 0.26-0.99) were significant protective factors. The only factor significantly related to relapse, which occurred in 11% of patients, was treatment with the combination of flucloxacillin and fusidic acid (OR = 0.32, 95% CI = 0.12-0.85). There was approximately a 70% reduction in the risk of relapse if this combination was used. Conclusions: This retrospective analysis suggests a clinically important protective effect of fusidic acid against relapse in patients with S. aureus bacteremia. Although the results were adjusted for potential confounding factors, the possibility of bias remains. There is a need for a prospective randomized trial to evaluate the effectiveness of flucloxacillin and fusidic acid for treating S. aureus bacteremia. Key words: Staphylococcus aureus, bacteremia, fusidic acid, antibiotics INTRODUCTION and the presence of foreign bodies, although infection may arise without a predisposing factor. Infection with Staphylococcus aureus is the most fiequent cause of S. aureus is frequently associated with bacteremia and bacteremia due to Gram-positive bacteria and the metastatic disease [6-81. commonest cause of wound infection in the UK. The Conflicting observations have resulted in un- reported mortality associated with S. aureus bacteremia certainty concerning the optimum duration of anti- ranges fiom 21% to 43% [l-51. Factors that preckspose biotic therapy for bacteremia caused by S. aureus [8]. to infection with S. aureus include breaches in the skin Many believe that all patients with S. aureus bacteremia should be treated with a 4-6 week course of intra- venous antibiotics [9,10] in order to prevent serious sequelae such as endocarditis. Recently, some authors Corresponding author and reprint requests: have suggested that shorter courses of therapy for Pauline E. Gosden, Department of Microbiology, Level 8, catheter-related bacteremia and uncomplicated right- Bristol Royal Infirmary, United Bristol Healthcare Trust, sided endocarditis in intravenous drug users would be Marlborough Street, Bristol, BS2 8HW. UK adequate [ll-161, whereas others have maintained that Tel: 0117-9282567 Fax: 01 17-9299162 short-course therapy results in unacceptable rates of Accepted 17 August 1996 complication and relapse [17,18]. 32 Gosden et al: Outcome in patients treated for Staph. aureus bacteremia 33 Fusidic acid is frequently used in the UK but rarely micin, fusidic acid and erythromycin [22]. Suscepti- in the USA [19,20]. Use of fusidic acid was not bility to methicillin was determined with a paper emphasized in the laboratory recommendations for strip containing 25 pg methicillin, on blood agar and the treatment of S. aureus bacteremia in the United mannitol salt plates incubated at 30°C and 37OC Bristol Hospital Trust (UBHT) complex of hospitals respectively. until 1991, when a laboratory recommendation of Demographic data recorded from the notes flucloxacillin and fusidic acid, given as the sodium salt included date of birth, sex, age at time of the positive for 4 weeks, was introduced. blood culture, and whether infection was acquired in At dus time it was felt that an antibiotic combina- the community or the hospital. Associated condtions tion including hsidc acid would, because of its better whch might influence outcome, such as malignancy, tissue penetration, offer benefit in terms of outcome for diabetes mellitus, rheumatoid arthritis, cardiac disease, the patient over a combination involving an amino- intravenous drug use and immunosuppression (asplenia, glycoside. We report a review of the outcome of steroid therapy, neutropenia, cytotoxic therapy), were patients treated for S. aureus bacteremia in the UBHT documented. Possible risk factors for infection, such between 1983 and 1993 with particular emphasis on as bone fracture, skin lesions, transcutaneous foreign the impact of the use of fusidic acid. bodies, operation within the previous year, prosthetic joints, bone screws and nails and prosthetic heart valves, were also recorded. Microbiological data included the PATIENTS AND METHODS date of the positive blood culture, and whether S. aureus was isolated &om the respiratory tract, urinary tract, Data were collected by a retrospective review of case skin/wound lesions or intravascular line tips. Treatment records for patients diagnosed and treated for S. aureus information recorded included antibiotics and their bacteremia between January 1983 and December 1993 duration of use. in the UBHT hospital complex. These hospitals form Information about the outcome of treatment a large teaching hospital unit with regional specialities included the date of death, whether death was related including cardiac surgery, oncology services and neo- to infection and whether a relapse occurred. The natal intensive care. In 1993, 54 000 inpatients were infection was classified as community acquired if the treated in the UBHT. In addtion to drawing patients blood cultures had been collected within 48 h of from the central and south Bristol areas, it also acts as hospital admission &om the community and as hospital a referral centre for the southwest of England. The acquired in all other cases. A relapse was said to have Bristol catchment population was 361 000 in 1983, occurred if a patient developed a new suppurative rising to 370 000 in 1991 (estimates based on Office complication or blood culture with S. aureus within 5 of Population and Censuses Surveys 1993 mid-year years following cessation of antibiotic therapy. In 92% population). of cases, relapse occurred within 10 months. Phage The UBHT cases were identified by searching typing was documented in only three cases and showed laboratory records of blood cultures, collected between identical phage types for both isolates. Antibiotic January 1983 and December 1993, from which S. susceptibility profiles were identical in all cases with the aureus had been grown. Patients with no clinical diag- exception of one. Death was considered to be related nosis of infection and who were not treated for to infection (DRI) if the death resulted from acute infection, and those with polymicrobial bacteremia sepsis syndrome or a complication of S. aureus without corroborating clinical or laboratory evidence bacteremia, such as endocarditis. Post-mortem data of S. aureus infection, were excluded. were used when available. The method of obtaining blood cultures changed Information recorded fi-om the notes was trans- in July 1988. Prior to 1988, blood cultures were ferred to a database. Descriptive statistics for demo- performed by inoculation of 5-10 d of aseptically graphic and relevant clinical data were calculated, drawn blood into brain-heart infusion (Oxoid CM including the proportions of patients receiving fusidic 225, Unipath Ltd, Basingstoke) and thioglycollate acid and the proportion experiencing the outcomes of broths. Broth cultures were subcultured onto solid interest, in each year. The effects of various clinical media afker 2 and 7 days. After July 1988 a commercial factors and treatment combinations on each outcome automated blood culture system was adopted (Bactec were then investigated in more detail by statistical 660, Becton Dickinson UK Ltd, Oxford). Identifica- modeling using multiple logistic regression, allowing tion of S. aureus was carried out by standard methods estimates of odds ratios (ORs) for different factors to [21]. Antibiotic susceptibility was determined by Stokes' be obtained with and without adjustment for possible method for the following antibiotics: penicillin, genta- confounding variables. 34 Clinical Microbiology and Infection, Volume 3 Number 1, February 1997 RESULTS The number of cases in each year ranged from 15 to 45. There appeared to be an increase in the number The total number of patients for whom blood cultures of cases occurring over time, paralleling the increase in were requested &om 1985 to 1993 was 66 447 and total requests and positive blood cultures, despite an requests showed an upwards trend from 6523 in 1985 essentially constant catchment population (x2=23.65, to 9193 in 1993. Data for total requests were unobtain- degrees of fieedom 10, p<O.Ol; linear regression of able for 1983 and 1984, as laboratory computerization number of cases against time gave a p coefficient for was not implemented until 1985. The annual total of each year of 1.95 cases, p=0.004). These trends may all patients with positive blood cultures rose from 437 have been due to better detection of cases, better use in 1985 to 739 in 1993, but the proportion positive for of the laboratory or a real increase in numbers of cases. S. aureus remained constant at approximately 11% of The median age was 51.6 years with an inter- the total. Between January 1983 and December 1993, quartile range (41-43) of 20.8-68.5 years.
Recommended publications
  • Activity of Vancomycin Combined with Linezolid Against Clinical Vancomycin-Resistant Enterococcus Strains
    Basic research Activity of vancomycin combined with linezolid against clinical vancomycin-resistant Enterococcus strains Gulseren Aktas Department of Medical Microbiology, Faculty of Medicine, Istanbul University, Corresponding author: Istanbul, Turkey Gulseren Aktas Department of Medical Submitted: 16 April 2019 Microbiology Accepted: 12 July 2019 Faculty of Medicine Istanbul University Arch Med Sci Istanbul, Turkey DOI: https://doi.org/10.5114/aoms.2020.96400 Phone: 090 212 Copyright © 2020 Termedia & Banach 4142000/32417 Fax: 090 212 4142037 E-mail: Abstract [email protected] Introduction: Because multi-drug-resistant Gram-positive bacteria have been isolated frequently worldwide and are difficult to treat, alternative treatment choices are required. Combination antibiotherapies have a distinct advan- tage over monotherapies in terms of their broad spectrum and synergistic effect. In the present study, it was aimed to investigate the in vitro activity of vancomycin combined with linezolid against clinical vancomycin-resistant enterococci (VRE) strains with high-level aminoglycoside resistance. Material and methods: A total of 30 randomly selected clinical VRE strains were studied. Susceptibility to agents tested was investigated using broth microdilution assay. The inoculum of strain was adjusted to approximately 5 × 105 CFU/ml in the wells. The results were interpreted in accordance with Clinical and Laboratory Standards Institute guidelines. In vitro activities of anti biotics in combination were assessed using the broth microcheckerboard technique. The fractional inhibitory concentration indexes (FICIs) were inter- preted as follows: synergism, FICI ≤ 0.5; additive/indifference, FICI ≤ 0.5 – ≤ 4; antagonism, FICI > 4. Results: All strains were resistant to vancomycin and susceptible to linezolid. The MIC50,90 and MICrange values of antimicrobials were 512, 512, and 512–1024 µg/ ml for vancomycin; 2, 2, and 2–4 µg/ml for linezolid.
    [Show full text]
  • Aminoglycosides for Intra-Abdominal Infection: Equal to the Challenge? John A
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by VCU Scholars Compass Virginia Commonwealth University VCU Scholars Compass Publications from the Office of the Dean Office of the Dean 2004 Aminoglycosides for Intra-Abdominal Infection: Equal to the Challenge? John A. Bailey Saint Louis University Katherine S. Virgo Saint Louis University Joseph T. DiPiro Virginia Commonwealth University, University of Georgia, [email protected] See next page for additional authors Follow this and additional works at: http://scholarscompass.vcu.edu/pharmacy_dean_pubs Part of the Pharmacy and Pharmaceutical Sciences Commons This is a copy of an article published in Surgical Infections © 2004 copyright Mary Ann Liebert, Inc.; Surgical Infections is available online at: http://online.liebertpub.com. Downloaded from http://scholarscompass.vcu.edu/pharmacy_dean_pubs/13 This Article is brought to you for free and open access by the Office of the Dean at VCU Scholars Compass. It has been accepted for inclusion in Publications from the Office of the Dean by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Authors John A. Bailey, Katherine S. Virgo, Joseph T. DiPiro, Avery B. Nathens, Robert G. Sawyer, and John E. Mazuski This article is available at VCU Scholars Compass: http://scholarscompass.vcu.edu/pharmacy_dean_pubs/13 SURGICAL INFECTIONS Volume 3, Number 4, 2002 © Mary Ann Liebert, Inc. Aminoglycosides for Intra-Abdominal Infection: Equal to the Challenge? JEFFREY A. BAILEY, 1 KATHERINE S. VIRGO, 1 JOSEPH T. D IPIRO,2 AVERY B. NATHENS, 3 ROBERT G. SAWYER, 4 and JOHN E.
    [Show full text]
  • Roles of Specific Aminoglycoside-Ribosome Interactions in the Inhibition of Translation
    Downloaded from rnajournal.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press Roles of specific aminoglycoside-ribosome interactions in the inhibition of translation Lanqing Ying, Hongkun Zhu, Shinichiro Shoji, and Kurt Fredrick* Department of Microbiology and Center for RNA Biology, The Ohio State University, Columbus, Ohio, 43210, USA *To whom correspondence should be addressed: Tel: +1 614 292 6679; Fax: +1 614 292 8120; E-mail: [email protected] Running title: Inhibition of ribosomes by aminoglycosides Key words: protein synthesis, ribosome, translocation, tRNA, mRNA 1 Downloaded from rnajournal.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract Aminoglycosides containing a 2-deoxystreptamine core (AGs) represent a large family of antibiotics that target the ribosome. These compounds promote miscoding, inhibit translocation, and inhibit ribosome recycling. AG binding to helix h44 of the small subunit induces rearrangement of A-site nucleotides (nt) A1492 and A1493, which promotes a key open-to- closed conformational change of the subunit and thereby increases miscoding. Mechanisms by which AGs inhibit translocation and recycling remain less clear. Structural studies have revealed a secondary AG binding site in H69 of the large subunit, and it has been proposed that interaction at this site is crucial for inhibition of translocation and recycling. Here, we analyze ribosomes with mutations targeting either or both AG binding sites. Assaying translocation, we find that ablation of the h44 site increases the IC50 values for AGs dramatically, while removal of the H69 site increases these values modestly. This suggests that AG-h44 interaction is primarily responsible for inhibition, with H69 playing a minor role.
    [Show full text]
  • Farrukh Javaid Malik
    I Farrukh Javaid Malik THESIS PRESENTED TO OBTAIN THE GRADE OF DOCTOR OF THE UNIVERSITY OF BORDEAUX Doctoral School, SP2: Society, Politic, Public Health Specialization Pharmacoepidemiology and Pharmacovigilance By Farrukh Javaid Malik “Analysis of the medicines panorama in Pakistan – The case of antimicrobials: market offer width and consumption.” Under the direction of Prof. Dr. Albert FIGUERAS Defense Date: 28th November 2019 Members of Jury M. Francesco SALVO, Maître de conférences des universités – praticien hospitalier, President Université de Bordeaux M. Albert FIGUERAS, Professeur des universités – praticien hospitalier, Director Université Autonome de Barcelone Mme Antonia AGUSTI, Professeure, Vall dʹHebron University Hospital Referee Mme Montserrat BOSCH, Praticienne hospitalière, Vall dʹHebron University Hospital Referee II Abstract A country’s medicines market is an indicator of its healthcare system, the epidemiological profile, and the prevalent practices therein. It is not only the first logical step to study the characteristics of medicines authorized for marketing, but also a requisite to set up a pharmacovigilance system, thus promoting rational drug utilization. The three medicines market studies presented in the present document were conducted in Pakistan with the aim of describing the characteristics of the pharmaceutical products available in the country as well as their consumption at a national level, with a special focus on antimicrobials. The most important cause of antimicrobial resistance is the inappropriate consumption of antimicrobials. The results of the researches conducted in Pakistan showed some market deficiencies which could be addressed as part of the national antimicrobial stewardship programmes. III Résumé Le marché du médicament d’un pays est un indicateur de son système de santé, de son profil épidémiologique et des pratiques [de prescription] qui y règnent.
    [Show full text]
  • Antibiotic Use in South Korea from 2007 to 2014: a Health Insurance Database-Generated Time Series Analysis
    RESEARCH ARTICLE Antibiotic use in South Korea from 2007 to 2014: A health insurance database-generated time series analysis Juhee Park1☯, Euna Han2☯, Soo Ok Lee1, Dong-Sook Kim1* 1 Department of Research, Health Insurance Review & Assessment Service, Wonju, Korea, 2 College of Pharmacy, Yonsei Institute of Pharmaceutical Science, Yonsei University, Seoul, Korea ☯ These authors contributed equally to this work. * [email protected] Abstract a1111111111 a1111111111 a1111111111 Background a1111111111 a1111111111 Inappropriate antibiotic use significantly contributes to antibiotic-resistance, resulting in reduced antibiotic efficacy and increasing physical burden and cost of disease. The goal of this study was to explore antibiotic usage patterns in South Korea using 2007±2014 health insurance claims data. OPEN ACCESS Methods Citation: Park J, Han E, Lee SO, Kim D-S (2017) Antibiotic use in South Korea from 2007 to 2014: A We used the Health Insurance Review & Assessment Service data, which represents nearly health insurance database-generated time series the entire population of South Korea, to discern patterns in antibiotic prescribing practices. analysis. PLoS ONE 12(5): e0177435. https://doi. The daily dose, as defined by the World Health Organization ([defined daily doses]/1000 org/10.1371/journal.pone.0177435 inhabitants/day, [DID]), was used as a measure of antibiotic use. Subgroup analyses were Editor: Yeng-Tseng Wang, Kaohsiung Medical performed on the basis of patient characteristics (sex, age, and disease) and provider char- University, TAIWAN acteristics (type of medical institution). Received: July 21, 2016 Accepted: April 20, 2017 Results Published: May 17, 2017 Antibiotic use in DID increased from 23.5 in 2007 to 27.7 in 2014.
    [Show full text]
  • Treatment with Sub-Inhibitory Kanamycin Induces Adaptive Resistance to Aminoglycoside Antibiotics Via the Acrd Multidrug Efflux Pump in Escherichia Coli K-12
    Journal of Experimental Microbiology and Immunology (JEMI) Vol. 16: 11 – 16 Copyright © April 2012, M&I UBC Treatment with Sub-inhibitory Kanamycin Induces Adaptive Resistance to Aminoglycoside Antibiotics via the AcrD Multidrug Efflux Pump in Escherichia coli K-12 Kiran Sidhu, Martha Talbot, Kirstin Van Mil, and Meghan Verstraete Department of Microbiology & Immunology, University of British Columbia Research has shown that exposing Escherichia coli cells to sub-inhibitory concentrations of kanamycin induces adaptive resistance upon subsequent exposure to lethal levels of both structurally-similar and unrelated antibiotics. AcrD is an efflux pump that forms a complex with the outer membrane pore TolC and the periplasmic membrane fusion protein AcrA. Together, this complex works to export a variety of aminoglycosides and amphiphilic compounds from the cell. The involvement of AcrD in the observed adaptive resistance was assessed by comparing the induction of adaptive resistance upon exposure to kanamycin in wild- type and acrD-deficient Escherichia coli strains. Both strains were pretreated with sub- inhibitory concentrations of kanamycin and subsequently exposed to lethal concentrations of ampicillin, kanamycin, nalidixic acid, streptomycin, and tetracycline. Growth was monitored over 18 hours via optical density readings. Comparing the relative growth of the different treatments revealed that adaptive resistance was only induced in the wild-type strain towards kanamycin and streptomycin. This indicates that AcrD is necessary for the induced adaptive resistance and that it is specific to aminoglycosides. Additionally, molecular techniques were used to assess the level of expression of acrA, which was found to be upregulated in both the wild-type and acrD deletion strains following pretreatment with kanamycin.
    [Show full text]
  • TETRACYCLINES and CHLORAMPHENICOL Protein Synthesis
    ANTIMICROBIALS INHIBITING PROTEIN SYNTHESIS AMINOGLYCOSIDES MACROLIDES TETRACYCLINES AND CHLORAMPHENICOL Protein synthesis Aminoglycosides 1. Aminoglycosides are group of natural and semi -synthetic antibiotics. They have polybasic amino groups linked glycosidically to two or more aminosugar like: sterptidine, 2-deoxy streptamine, glucosamine 2. Aminoglycosides which are derived from: Streptomyces genus are named with the suffix –mycin. While those which are derived from Micromonospora are named with the suffix –micin. Classification of Aminoglycosides 1. Systemic aminogycosides Streptomycin (Streptomyces griseus) Gentamicin (Micromonospora purpurea) Kanamycin (S. kanamyceticus) Tobramycin (S. tenebrarius) Amikacin (Semisynthetic derivative of Kanamycin) Sisomicin (Micromonospora inyoensis) Netilmicin (Semisynthetic derivative of Sisomicin) 2. Topical aminoglycosides Neomycin (S. fradiae) Framycetin (S. lavendulae) Pharmacology of Streptomycin NH H2N NH HO OH Streptidine OH NH H2N O O NH CHO L-Streptose CH3 OH O HO O HO NHCH3 N-Methyl-L- Glucosamine OH Streptomycin Biological Source It is a oldest aminoglycoside antibiotic obtained from Streptomyces griseus. Antibacterial spectrum 1. It is mostly active against gram negative bacteria like H. ducreyi, Brucella, Yersinia pestis, Francisella tularensis, Nocardia,etc. 2. It is also used against M.tuberculosis 3. Few strains of E.coli, V. cholerae, H. influenzae , Enterococci etc. are sensitive at higher concentration. Mechanism of action Aminoglycosides bind to the 16S rRNA of the 30S subunit and inhibit protein synthesis. 1. Transport of aminoglycoside through cell wall and cytoplasmic membrane. a) Diffuse across cell wall of gram negative bacteria by porin channels. b) Transport across cell membrane by carrier mediated process liked with electron transport chain 2. Binding to ribosome resulting in inhibition of protein synthesis A.
    [Show full text]
  • Synthesis of Netilmicin and Apramycin Derivatives for the Rt Eatment of Multidrug- Resistant Infectious Diseases Amr Sayed Motawi Sonousi Wayne State University
    Wayne State University Wayne State University Dissertations 1-1-2017 Synthesis Of Netilmicin And Apramycin Derivatives For The rT eatment Of Multidrug- Resistant Infectious Diseases Amr Sayed Motawi Sonousi Wayne State University, Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Organic Chemistry Commons Recommended Citation Sonousi, Amr Sayed Motawi, "Synthesis Of Netilmicin And Apramycin Derivatives For The rT eatment Of Multidrug-Resistant Infectious Diseases" (2017). Wayne State University Dissertations. 1880. https://digitalcommons.wayne.edu/oa_dissertations/1880 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. SYNTHESIS OF NETILMICIN AND APRAMYCIN DERIVATIVES FOR THE TREATMENT OF MULTIDRUG-RESISTANT INFECTIOUS DISEASES by AMR SONOUSI DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2017 MAJOR: CHEMISTRY (Organic) Approved By: Advisor Date DEDICATION I dedicate my PhD work to my parents Sayed Sonousi and Hoda Fayed for nursing me with affection and love and for their dedicated partnership for success in my life. I also dedicate my work to my wife Tasnim Kandeel for her endless love and support for me throughout the process. ii ACKNOWLEDGEMENTS I would first like to express my utmost appreciation to my advisor, Professor David Crich, for his endless patience, brilliant guidance, continuous encouragement, and constant support during the past five years of my Ph.D. studies. His passion and dedication for science will always be my example to follow.
    [Show full text]
  • Danmap 2006.Pmd
    DANMAP 2006 DANMAP 2006 DANMAP 2006 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark Statens Serum Institut Danish Veterinary and Food Administration Danish Medicines Agency National Veterinary Institute, Technical University of Denmark National Food Institute, Technical University of Denmark Editors: Hanne-Dorthe Emborg Danish Zoonosis Centre National Food Institute, Technical University of Denmark Mørkhøj Bygade 19 Contents DK - 2860 Søborg Anette M. Hammerum National Center for Antimicrobials and Contributors to the 2006 Infection Control DANMAP Report 4 Statens Serum Institut Artillerivej 5 DK - 2300 Copenhagen Introduction 6 DANMAP board: National Food Institute, Acknowledgements 6 Technical University of Denmark: Ole E. Heuer Frank Aarestrup List of abbreviations 7 National Veterinary Institute, Tecnical University of Denmark: Sammendrag 9 Flemming Bager Danish Veterinary and Food Administration: Summary 12 Justin C. Ajufo Annette Cleveland Nielsen Statens Serum Institut: Demographic data 15 Dominique L. Monnet Niels Frimodt-Møller Anette M. Hammerum Antimicrobial consumption 17 Danish Medicines Agency: Consumption in animals 17 Jan Poulsen Consumption in humans 24 Layout: Susanne Carlsson Danish Zoonosis Centre Resistance in zoonotic bacteria 33 Printing: Schultz Grafisk A/S DANMAP 2006 - September 2007 Salmonella 33 ISSN 1600-2032 Campylobacter 43 Text and tables may be cited and reprinted only with reference to this report. Resistance in indicator bacteria 47 Reprints can be ordered from: Enterococci 47 National Food Institute Escherichia coli 58 Danish Zoonosis Centre Tecnical University of Denmark Mørkhøj Bygade 19 DK - 2860 Søborg Resistance in bacteria from Phone: +45 7234 - 7084 diagnostic submissions 65 Fax: +45 7234 - 7028 E.
    [Show full text]
  • Pharmacokinetic Training Packet for Pharmacists
    Pharmacokinetic Training Packet for Pharmacists Revised 1/09, 6/12 Original document compiled by: Elizabeth D. Hermsen, Pharm.D., M.B.A., BCPS-ID Updated by: Alan Gross, Pharm.D., BCPS Thanks to Erin Iselin, Scott McMullen, Chris Shaffer, & Keith Olsen for your thoughtful review! Any questions? Call or email Alan Gross at 559-4149/[email protected] Table of Contents Pharmacokinetic definitions and principles 3 Aminoglycoside overview 4 Extended-interval (Once daily) aminoglycoside dosing 8 Aminoglycoside pharmacokinetic calculations 10 Aminoglycoside dosing in patients with cystic fibrosis 12 Vancomycin overview and pharmacokinetic calculations 15 Clinical Pearls 21 Dialysis – Aminoglycosides and Vancomycin 21 TNMC Nephrology Protocol for Vancomycin Dosing 21 Clinical Pharmacokinetic Consult Service 23 2 Pharmacokinetic Definitions and Principles Kel, Ke, or Kd or Elimination Rate Constant 1 • The fraction or percentage of the total amount of drug in the body eliminated per unit of time. • Estimated with 2 drug levels taken between doses (the slope of the line). To be accurate, 2-4 half-lives should occur between the levels.1 -kel(τ) • In pharmacokinetic calculations, the term e represents the fraction of the serum concentration that remains. Thus, 1 - e- kel(τ) represents the fraction of the serum concentration that is eliminated. t 1/2 or Half-life 1 • The time required for the TOTAL amount of remaining drug in the body to decline by 50%. • Sometimes referred to as β t ½ to distinguish it from the distribution half-life, α t ½, used in two compartment modeling.1 Peak, C max1 • C max is the maximum measurable drug concentration at the end of an infusion BEFORE significant distribution occurs.
    [Show full text]
  • The First Linezolid‑Resistant Enterococcus Faecium in India: High Level Resistance in a Patient with No Previous Antibiotic Exposure
    Published online: 2021-08-09 CASE REPORT The first linezolid‑resistant Enterococcus faecium in India: High level resistance in a patient with no previous antibiotic exposure Simit Kumar, Maitreyi Bandyoapdhyay, Mitali Chatterjee, Prabir Mukhopadhyay, Sumon Poddar, Parthajit Banerjee Department of Microbiology, R.G. Kar Medical College and Hospital, Kolkata, West Bengal, India Access this article online ABSTRACT Website: www.avicennajmed.com DOI: 0.4103/2231-0770.127416 Linezolid provides high rates of the clinical cure and microbiological success in complicated Quick Response Code: infections due to Enterococcus spp., including vancomycin‑resistant Enterococcus faecium. However, the emergence of resistance during linezolid treatment has been reported for clinical strains of Enterococcus, which is alarming given the fact that, this leaves the clinician with very few treatment options. We report the first case of linezolid resistantEnterococcus faecium from India, which was isolated from the blood culture of a hypoglycemic encephalopathy patient. There have been previous reports of linezolid resistant enterococci from different parts of the world, with minimum inhibitory concentration (MIC) ranging from 16 to 64 µg/mL and most of them were associated with vancomycin resistance but the isolate reported over here had an MIC of 1024 µg/mL and interestingly was sensitive to vancomycin. Key words: Enterococcus faecium, linezolid resistant, testing methods for detecting linezolid minimum inhibitory concentration INTRODUCTION isolates found to date. Previously reported patient factors that might pre‑dispose to the development of linezolid Linezolid, a member of the oxazolidinone class of antibiotics, resistance include indwelling intravascular devices, under exerts antibacterial activity by inhibiting the formation of dosage, immunosuppression after transplantation and the 70S initiation complex.
    [Show full text]
  • Trend Analysis of Antibiotics Consumption Using WHO Aware Classification in Tertiary Care Hospital
    International Journal of Basic & Clinical Pharmacology Bhardwaj A et al. Int J Basic Clin Pharmacol. 2020 Nov;9(11):1675-1680 http:// www.ijbcp.com pISSN 2319-2003 | eISSN 2279-0780 DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20204493 Original Research Article Trend analysis of antibiotics consumption using WHO AWaRe classification in tertiary care hospital Ankit Bhardwaj*, Kaveri Kapoor, Vivek Singh Saraswathi institute of Medical Sciences, Pilakhuwa, Hapur, Uttar Pradesh, India Received: 21 August 2020 Accepted: 21 September 2020 *Correspondence: Dr. Ankit Bhardwaj, Email: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Aim of the study was to assess trend in antibiotics consumption pattern from 2016 to 2019 using AWaRe classification, ATC and Defined daily dose methodology (DDD) in a tertiary care hospital. Antibiotics are crucial for treating infectious diseases and have significantly improved the prognosis of patients with infectious diseases, reducing morbidity and mortality. The aim of the study is to classify the antibiotic based on WHO AWaRe classification and compare their four-year consumption trends. The study was conducted at a tertiary care center, Pilakhuwa, Hapur. Antibiotic procurement data for a period of 4 years (2016-2019) was collected from the Central medical store. Methods: This is a retrospective time series analysis of systemic antibiotics with no intervention at patient level. Antibiotic procurement was taken as proxy for consumption assuming that same has been used.
    [Show full text]